Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Radiation oncologists head to Capitol Hill to promote critical initiatives

More than 100 radiation oncology treatment team members and resident physicians convened in Washington Monday and Tuesday to represent radiation oncology on Capitol Hill at the American Society for Radiation Oncology's (ASTRO) eighth annual Advocacy Day. Participants spent Monday hearing from members of Congress and key congressional staff on the latest legislative activity and ASTRO'’s legislative agenda. On Tuesday, the group headed to House and Senate office buildings to meet with senators, congressmen and staffers from their home states to promote agenda items important to the safety and well-being of cancer patients.

30 Mar 2011

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

Roche launces new GS GType HLA Primer Sets for HLA genotyping

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci of the Human Leukocyte Antigen (HLA) genes.

30 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February.

30 Mar 2011

Dr. Reddy’s acquires GSK's US penicillin facility and products

Dr. Reddy's Laboratories today announced the completion of the acquisition of GlaxoSmithKline's United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

CancerForward announces new national outreach and partnering program

CancerForward: The Foundation for Cancer Survivors today announced the creation of ConnectToForward, a fundamental initiative of the Foundation's three-prong mission to connect, educate and share information among cancer survivors through its website, cancerforward.org.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Cephalon receives unsolicited proposal from Valeant

Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.

30 Mar 2011

Navy sonar experts develop new medical device for stroke detection

A medical device developed by retired U.S. Navy sonar experts, using submarine technology, is a new paradigm for the detection, diagnosis and monitoring of stroke, says a team of interventional radiologists at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization—an interventional radiology treatment for the noncancerous yet very common growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids, confirm researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

Roundup: Ariz. may restore transplant coverage; Fla. faces class action suit over disabled waiting list

Kentucky health officials are considering restrictions on the number of cancer-fighting drugs Medicaid patients may receive without prior approval, a move designed to contain costs in the health care program for the poor and disabled. The possibility of creating a non-preferred list of oral oncology drugs — pills that replace intravenous chemotherapy drugs — that Medicaid won't pay for without prior approval has raised questions from patient advocates and those who treat cancer patients.

30 Mar 2011

Oral antioxidant formulation before medical imaging may minimize cell damage

A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

New lung cancer drug starts human trials

A new drug for lung cancer is being tried by researchers at Oxford. The treatment, which halts the growth of cancer cells, is being trialed on those patients who have stopped responding to chemotherapy. The trial is one of the first to go ahead at the Oxford Cancer Research Centre.

29 Mar 2011

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.

29 Mar 2011